Recent Updates
Recently added Catalysts
A Positive Sentiment

Agilent Expands Tumor Profiling Portfolio with SureSelect Cancer Research Pan Heme

Tuesday, November 10, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Agilent Technologies has launched the SureSelect Cancer Research Pan Heme, a new hybrid capture-based NGS solution. This tool is designed for comprehensive genomic profiling of hematologic malignancies and was developed with experts from Roswell Park Comprehensive Cancer Center. It features integrated DNA and RNA profiling along with automated sample preparation.

Market Sentiment Analysis

POSITIVE FACTORS

  • Launch of a new comprehensive genomic profiling solution
  • Collaboration with Roswell Park Comprehensive Cancer Center
  • Integration of DNA and RNA profiling in one workflow

Full Press Release Details

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the SureSelect Cancer Research Pan Heme, a hybrid capture-based next-generation sequencing (NGS) research solution for comprehensive genomic profiling of hematologic malignancies. Developed in collaboration with experts at Roswell Park Comprehensive Cancer Center, the solution integrates DNA and RNA profiling, automated sample preparation and bioinformatics in a streamlined workflow. The introduction of Su

Frequently Asked Questions

What is the SureSelect Cancer Research Pan Heme?

It is a hybrid capture-based NGS solution for genomic profiling of hematologic malignancies.

Who developed the SureSelect Pan Heme?

Agilent developed it in collaboration with Roswell Park Comprehensive Cancer Center.

What features does the Pan Heme offer?

It integrates DNA and RNA profiling with automated sample preparation.

What is the purpose of the Pan Heme?

It aims to provide comprehensive genomic profiling for cancer research.

ShareAdd on Google
Tags: A Agilent Technologies SureSelect genomic profiling hematologic malignancies Roswell Park
Last updated: Nov 10, 2026

Biotech snapshot

Cash runway
$1758M liquidity · $0M/mo burn
Low dilution risk